Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.48 |
| ▸ | BTK | Q06187 | 3/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | CIT | O14578 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16794005 | 1.00 | AAK1 (0.48) | AAK1BTKMKNK1MKNK2ROCK2 | |
| SCHEMBL22664870 | 0.85 | AAK1 (0.42) | AAK1BTKMKNK2ROCK2HDAC1 | |
| SCHEMBL16794245 | 0.84 | BTK (0.62) | AAK1BTKPDPK1MAP4K4 | |
| SCHEMBL16794160 | 0.84 | MKNK1 (0.48) | BTKMKNK1MKNK2ROCK2CIT | |
| SCHEMBL17681842 | 0.84 | BTK (0.42) | AAK1BTKMAP4K4 | |
| SCHEMBL16793748 | 0.84 | BTK (0.63) | AAK1BTKROCK2 | |
| SCHEMBL29533531 | 0.81 | GSK3B (0.48) | — | |
| SCHEMBL22660077 | 0.81 | GSK3B (0.48) | — | |
| SCHEMBL20328422 | 0.81 | AAK1 (0.59) | AAK1BTK | |
| SCHEMBL16794118 | 0.79 | AAK1 (0.54) | AAK1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109096274-B | Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases | 比奥根MA公司 | 2022-07-01 | — | — | CN | disclosed |